journal
MENU ▼
Read by QxMD icon Read
search

Current Radiopharmaceuticals

journal
https://www.readbyqxmd.com/read/29972107/stability-study-of-18f-fludeoxyglucose-and-18f-fluorocholine-in-different-medical-devices-for-intravenous-administration
#1
F Hallouard, W Sauze, S Emery, A Skanjeti, C Rioufol, M Fraysse
[18F]-radiopharmaceuticals registered as ready-to-use drugs are prepared in multi-dose flasks. When the change of packaging must be made extemporaneously for the preparation of patient unit doses in a syringe or cartridge, this is under the responsibility of radiopharmacists. As drug quality in medical devices (syringe or cartridge) is not evaluated during the marketing authorization of such radiopharmaceuticals, an evaluation of drug stability in such devices seems interesting. In addition, if there are difficulties in patient care (placement of the catheter, lack of personal, etc…) or equipment problems (technical issue with the automated dispenser delaying the delivery of the prepared dose), the contact time of [18F]-radiopharmaceuticals with the medical devices (cartridge or syringe) increases...
July 3, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29956640/final-outcome-of-223ra-therapy-and-the-role-of-18f-fluoride-pet-in-response-evaluation-in-metastatic-castration-resistant-prostate-cancer-a-single-institution-experience
#2
Kalevi Kairemo, Denai R Milton, Elba Etchebehere, Eric M Rohren, Homer A Macapinlac
BACKGROUND: 223Ra was the first therapeutic alpha-emitting radionuclide registered for clinical practice. This radionuclide is targeting actively bone forming cells, and it is approved for treating metastatic skeletal disease in prostate cancer. 18F-PET is used to detect skeletal metastatic disease based on osteoblastic activity. The aim of this study was to analyze, if 18F-PET can be used assessing the results of 223Ra therapy, and to report final median overall survival in a total of 773 therapy cycles...
June 29, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29866026/in-vivo-evaluation-of-225ac-ac-dotazol-for-%C3%AE-therapy-of-bone-metastases
#3
Nina Pfannkuchen, Nicole Bausbacher, Stefanie Pektor, Matthias Miederer, Frank Rosch
Background Conjugates of bisphosphonates with macrocyclic chelators possess high potential in bone targeted radionuclide imaging and therapy. DOTAZOL, zoledronic acid conjugated to DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), demonstrated promising results in vivo in small animals as well as in first patient applications using 68Ga for diagnosis via PET and the low-energy β-emitter 177Lu for therapy of painful bone metastases. In consideration of the fact that targeted α-therapy probably offers various advantages over the use of β--emitters, the 225Ac-labelled derivative [225Ac]Ac-DOTAZOL was synthesized and evaluated in vivo...
June 3, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29807525/development-and-evaluation-of-liquid-and-solid-lipid-based-drug-delivery-systems-containing-technetium-99m-radiolabeled-alendronate-sodium
#4
Evren Gundogdu, Meliha Ekinci, Emre Ozgenc, Derya Ilem Ozdemir, Makbule Asikoglu
OBJECTIVE: The purpose of this study was to develop lipid-water based drug delivery system of Alendronate Sodium (ALD) in liquid and solid form obtained by using spray drying method and compare these two forms with radioactive cell culture studies. METHODS: This study included that development of liquid and solid form obtained by spray drying method, radiolabelling of ALD with 99mTc, preparation of formulations containing 99mTc -ALD and evaluation of their permeability with Caco-2 cell...
May 28, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29804541/radioprotective-effect-of-cerium-oxide-nanoparticles-against-genotoxicity-induced-by-ionizing-radiation-on-human-lymphocytes
#5
Zohreh Zal, Arash Ghasemi, Shima Azizi, Hossein Asgarian-Omran, Azadeh Montazeri, Seyed Jalal Hosseinimehr
BACKGROUND: Ionizing radiation induces DNA damage on normal cell results in apoptosis and cell deaths. OBJECTIVES: The radioprotective effects of cerium oxide nanoparticles (CNPs) on genotoxicity, apoptosis and necrosis induced by ionizing radiation (IR) in human normal lymphocytes as highly radiosensitive cells were investigated. MATERIALS AND METHODS: Lymphocytes were pretreated with CNPs at different concentrations and were exposure to IR...
May 27, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29804540/pet-evaluation-of-late-cerebral-effect-in-advanced-radiation-therapy-techniques-for-cranial-base-tumors
#6
Pierpaolo Alongi, Leonardo Iaccarino, Marco Losa, Antonella Del Vecchio, Simonetta Gerevini, Valentina Plebani, Nadia Di Muzio, Pietro Mortini, Luigi Gianolli, Daniela Perani
BACKGROUND AND OBJECTIVE: Even though the benefits of radiation therapy are well established, it is important to recognize the broad spectrum of radiation-induced changes, particularly in the central nervous system. The possible damage to the brain parenchyma may have clinical consequences and in particular cognitive impairment might be one of the major complication of radiotherapy. To date, no studies have investigated the effects of focal radiation therapy on brain structure and function together with the assessment of their clinical outcomes at a long follow-up...
May 25, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29793418/clinical-studies-with-bismuth-213-and-actinium-225-for-hematologic-malignancies
#7
Joseph G Jurcic
Because α-particles have a shorter range and a higher linear energy transfer compared to β-particles, targeted α-particle therapy offers the potential for more efficient tumor cell killing while sparing surrounding normal cells. To date, clinical studies of α-particle therapy for acute myeloid leukemia (AML) have focused on targeting the cell surface antigen CD33 using the humanized monoclonal antibody lintuzumab. An initial phase I study showed the safety feasibility, and anti-leukemic effects of bismuth-213 (213Bi)-labeled lintuzumab...
May 24, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29766832/northstar-perspectives-for-actinium-225-production-at-commercial-scale
#8
James T Harvey
Actinium-225, and its daughter bismuth-213, have great promise in alpha immuno therapy (AIT) for treatment of various disease modalities. Unfortunately, current production levels of actinium-225 that are commercially available do not support broad use of either actinium-225 or bismuth-213 in development or use for disease treatment. Further, the current cost per millicurie is much too high to be sustainable long term in the market. Resolution of both supply and cost issues allows clinical research to proceed through clinical trials and potentially produce one or more effective therapies for cancer or infectious diseases that could benefit the public...
May 15, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29745348/automated-synthesis-of-68ga-dota-toc-methodological-aspects-and-suitable-technical-solutions-for-a-cationic-purification-system
#9
Licia Uccelli, Alessandra Boschi, Corrado Cittanti, Petra Martini, Luca Lodi, Elisa Zappaterra, Simona Romani, Samanta Zaccaria, Davide Cecconi, Ilaria Rambaldi, Ivan Santi, Stefano Panareo, Melchiore Giganti, Mirco Bartolomei
The PET Gallium-68 isotope has the advantage of being produced from a generator, so it is also available in nuclear medicine departments without a cyclotron. The preparation of Ga-68 DOTA-labelled compounds is actually performed by remotely controlled automated systems developed in order to assure production efficiency, reproducibility of the results, guarantee fast reaction time, to facilitate the synthesis and minimize the radiation exposure. Many automatic synthesis systems are available on the radiopharmaceutical market, and each of these requires the realization of some technical adaptations for routine use...
May 8, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29732998/an-overview-of-targeted-alpha-therapy-with-225actinium-and-213bismuth
#10
Alfred Morgenstern, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki, Frank Bruchertseifer
Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy. This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
May 1, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29697036/dosimetry-and-radiobiology-of-alpha-particle-emitting-radionuclides
#11
George Sgouros, Robert Hobbs, Anders Josefsson
Radiopharmaceutical therapy is a cancer treatment modality by which radiation is delivered directly to targeted tumor cells or to their microenvironment. This makes it possible to deliver highly potent alpha-particle radiation. The short-range and highly potent nature of alpha-particles requires a dosimetry methodology that considers microscale distributions of the alpha-emitting agent. The high energy deposition density along an alpha-particle track causes a spectrum of DNA lesions. The majority of these are irreparable DNA double-stranded breaks...
April 26, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29683101/in-vivo-evaluation-of-free-and-chelated-accelerator-produced-actinium-225-radiation-dosimetry-and-toxicity-results
#12
Zewei Jiang, Ekaterina Revskaya, Darrell R Fisher, Ekaterina Dadachova
OBJECTIVE: The demand for the alpha-emitting radionuclide Actinium-225 (225Ac) for use in radionuclide therapy is growing. Producing 225Ac using high energy linear accelerators, cyclotrons or photoinduction could increase its supply. One potential problem with accelerator produced 225Ac using Thorium-232 targets is the presence in final product of 0.1-0.3% by activity of the long-lived 227Ac impurity at the end of irradiation. It is important to comprehensively evaluate the behavior of accelerator-produced 225Ac in vivo before using it in pre-clinical and clinical applications...
April 23, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29676240/motion-management-in-pet-ct-technological-solutions
#13
Elena De Ponti, Sabrina Morzenti, Cinzia Crivellaro, Federica Elisei, Andrea Crespi, Luca Guerra
BACKGROUND: Motion due to patient's breathing can introduce heavy bias in PET/CT, both in image quality and quantification. AIM: To review technical aspects of the main solutions available to manage movement in PET/CT studies. METHODS: The following tools were described: Respiratory Gated (RG), Motion Free (MF), End Expiration (EE), Banana Artefact Management (BAM) and Data Driven Gating (DDG). RESULTS: The most diffused solutions (RG, MF, EE) are based on LIST mode acquisition of a PET Field of View (4D FOV), centered on the anatomical region of interest; to link PET data not only to time and to spatial position but also to the corresponding breathing phase, the synchronized acquisition of the patient's breathing curve is performed by an external tracking device...
April 19, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29669509/the-production-of-ac-225
#14
Jonathan W Engle
The radionuclide 225Ac and its daughter 213Bi are among the most interesting alpha emitters being evaluated for incorporation into targeted therapeutic vectors. Global supply of 225Ac is presently insufficient to meet anticipated clinical demand, but the deficiency has been targeted by many research and development efforts, privately and publicly funded. From more than a decade of these endeavors, no single production technology has emerged as a complete solution. In the foreseeable future, global supply of 225Ac will continue to be sourced from a patchwork of production methods and laboratories with a range of radioisotopic purities and achievable yields...
April 18, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29667558/ga-68-nanoparticles-and-ultra-small-nanoparticle-next-generation-of-pet-radiopharmaceuticals
#15
Mohammed Al-Qahtani, Yousif Al Malki, Hadeel Mutwali, Edward Helal-Neto, Ralph Santos-Oliveira
BACKGROUND AND OBJECTIVE: The future of medicine relies on the capability to forecast the future and in the development of new drugs. The same rationale is applied to radiopharmacy. In this direction the development of nano-radiopharmaceuticals represents the most effective glance of the future. METHODS: In this manuscript we developed an efficient, rapid and direct methodology to label ultra-small polymeric nanoparticle (10 to 12 nm) and regular polymeric nanoparticles (200 to 210 nm), both obtained by double emulsion technique, with Ga-68 in order to promote the development of PET-nanoradiopharmaceuticals...
April 17, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29658444/development-of-225ac-radiopharmaceuticals-triumf-perspectives-and-experiences
#16
A Kh Robertson, C F Ramogida, P Schaffer, V Radchenko
The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide. Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges that must be overcome to realize the widespread clinical use of 225Ac. Some of these challenges include the limited availability of the isotope, the challenging chemistry required to isolate 225Ac from any co-produced isotopes, and the need for stable targeting systems with high radiolabeling yields...
April 16, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29651974/preparation-and-dosimetry-evaluation-of-a-carrier-free-90y-labeled-dotmp-as-a-promising-agent-for-bone-marrow-ablation
#17
Nafise Salek, Sara Vosoghi, Simindokht Shirvani Arani, Ali Bahrami Samani, Mohsen Mehrabi, Mohammad Ghannadi Maraghe
BACKGROUND AND OBJECTIVE: Skeletal uptake of 90Y-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) is used to deliver high doses of this radiopharmaceutical to the bone marrow. METHODS: In this research, carrier-free (c.f.) 90Y was obtained from an electrochemical 90Sr/90Y generator. The c.f. 90Y was mixed with 300 µL of DOTMP (20 mg/mL) and incubated under stirring conditions at room temperature for 45 min. RESULTS: The [90Y]Y-DOTMP that was obtained under optimized reaction conditions had the high radiochemical purities (>98%)...
April 12, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29651945/modeling-of-a-cyclotron-target-for-the-production-of-11c-with-geant4
#18
Andrea Chiappiniello, Federico Zagni, Angelo Infantino, Sara Vichi, Gianfranco Cicoria, Maria Pia Morigi, Mario Marengo
BACKGROUND: In medical cyclotron facilities, 11C is produced according to the 14N(p,α)11C reaction and widely employed in studies of prostate and brain cancers by Positron Emission Tomography. It is known from literature [1] that the 11C-target assembly shows a reduction in efficiency during time, meaning a decrease of activity produced at the end of bombardment. This effect might depend on aspects still not completely known. OBJECTIVE: Possible causes of the loss of performance of the 11C-target assembly were addressed by Monte Carlo simulations...
April 12, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29624156/letter-to-the-editor-international-consensus-radiochemistry-nomenclature-guidelines
#19
LETTER
Heinz H Coenen, Antony D Gee, Michael Adam, Gunnar Antoni, Cathy S Cutler, Yasuhisa Fujibayashi, Jae Min Jeong, Robert H Mach, Thomas L Mindt, Victor W Pike, Albert D Windhorst
No abstract text is available yet for this article.
2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29624155/preface
#20
Luigi Mansi, Sean L Kitson
No abstract text is available yet for this article.
2018: Current Radiopharmaceuticals
journal
journal
41909
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"